/Edwards%20Lifesciences%20Corp%20Irvine%2C%20Ca%20campus-by%20Steve%20Cukrov%20via%20Shutterstock.jpg)
Valued at approximately $47.8 billion by market capitalization, California-based Edwards Lifesciences Corporation (EW) develops products and technologies to treat advanced cardiovascular diseases across the United States, Europe, Japan, and other international markets. Companies with valuations of $10 billion or more are generally classified as “large-cap” stocks, and Edwards Lifesciences comfortably fits into this category.
As the world’s leading structural heart innovation company, Edwards Lifesciences is driven by its mission to improve patient outcomes. Through breakthrough technologies, robust clinical evidence, and close collaboration with clinicians and healthcare partners, the company continues to deliver meaningful advances in cardiovascular care, guided by a strong patient-centered culture.